Maze Therapeutics, Inc.
NASDAQ:MAZEBiotechnology
+$0.18 today
- Market cap
- $1.71B
- Beta
- 2.26
- P/E (TTM)
- -11.0
- EPS (TTM)
- -$2.27
Volume 0.71M
Average 0.84M
MAZE Long-term Investments
Investments the company intends to hold for more than a year.
Maze Therapeutics, Inc.NASDAQ: MAZE
Long-term Investments · Q1 FY2026 · quarter ended Mar 2026
Long-term investments rises 869.3% from a year ago
Long-term investments stood at $10.56M at the end of Q1 FY2026, up 869.3% from a year earlier and down 41.7% from the prior quarter. Over 3 fiscal years it compounded at +146.5% a year.
Context
- Long-term investments amounted to 2.5% of total assets at the end of Q1 FY2026, up 2.2 pp from a year earlier.
- Long-term investments increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether long-term investments keeps rising in the next quarterly balance sheet after a +869.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Long-term Investments history
USD · from the balance sheet
- Latest · FY2025
- 18.11M USD
- Year-over-year change
- +1564.9%
- 3-year CAGR
- +146.5%
| Period | Period end | Long-term Investments | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 18.11M | +1564.9% |
| FY2024 | 2024-12-31 | 1.09M | +0.0% |
| FY2023 | 2023-12-31 | 1.09M | -10.1% |
| FY2022 | 2022-12-31 | 1.21M | — |
Long-term Investments vs competitors
How MAZE compares with its peers on the latest reported figures
- Peers report in different currencies, so long-term investments is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +869.3% is the highest of 5, against a peer median of -99.7%.
- Long-term investments amounts to 2.5% of total assets for MAZE, versus a peer median of 0.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $10.56M USD | +869.3% | +146.5% | 2.5% | |
| Dec 2025 | €526.78K EUR | -53.8% | -9.0% | 0.2% | |
BIOABioAge Labs, Inc. | Mar 2026 | $100K USD | -99.3% | — | 0.0% |
| Jun 2026 | $0 USD | — | — | 0.0% | |
| Sep 2026 | $0 USD | — | — | 0.0% | |
SEPNSepterna, Inc. | Sep 2026 | $0 USD | -100.0% | — | 0.0% |
| Mar 2026 | $0 USD | — | — | 0.0% | |
| Mar 2026 | $0 USD | -100.0% | — | 0.0% | |
| Peer median (excluding MAZE) | — | -99.7% | -9.0% | 0.0% | |
Competitors are the stored peer set for MAZE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Maze Therapeutics, Inc.
NASDAQ:MAZE
Intrinsic Alpha fair value
Locked
Current Price
$31.20
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.